Horizon Pharma Plc (HZNP): Virinder Nohria , director of Horizon Pharma Plc sold 25,000 shares on Jun 15, 2016. The Insider selling transaction was reported by the company on Jun 15, 2016 to the Securities and Exchange Commission. The shares were sold at $17.69 per share for a total value of $442,280.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Dec 10, 2015, Jeffrey W Sherman (EVP and Chief Medical Officer) sold 4,456 shares at $20.00 per share price.On Aug 21, 2015, Thomas Watkins (director) purchased 10,000 shares at $31.32 per share price.Also, On Mar 17, 2015, Jeff Himawan (director) sold 554,564 shares at $22.47 per share price.
Shares of Horizon Pharma PLC (HZNP) ended Wednesday, Jun 15, 2016 session in red amid volatile trading. The shares closed down -0.18 points or -1.02% at $17.45 with 21,48,613 shares getting traded. Post opening the session at $17.8, the shares hit an intraday low of $17.41 and an intraday high of $17.8899 and the price vacillated in this range throughout the day. The company has a market cap of $2,798 M and the number of outstanding shares has been calculated to be 16,03,56,710 shares. The 52-week high of Horizon Pharma PLC is $39.49 and the 52-week low is $12.86.
Company has been under the radar of several Street Analysts.Horizon Pharma PLC is Initiated by Goldman to Buy and the brokerage firm has set the Price Target at $24. The Rating was issued on Jun 6, 2016.Horizon Pharma PLC is Reiterated by Mizuho to Buy while Lowering the Price Target of the company shares to $ 24 from a previous price target of $25 . The Rating was issued on May 10, 2016.Horizon Pharma PLC is Reiterated by Mizuho to Buy while Lowering the Price Target of the company shares to $ 25 from a previous price target of $34 . The Rating was issued on May 3, 2016.
Horizon Pharma plc formerly Vidara Therapeutics International Public Limited Company is a specialty biopharmaceutical company focused on identifying developing acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis inflammation and orphan diseases. The Company’s the United States marketed products are ACTIMMUNE (interferon gamma-1b) DUEXIS (ibuprofen/famotidine) PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%) RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA has the United States rights to VIMOVO has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.